Satoh T, Barthelemy P, Nogova L, Honda K, et al. Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications. Eur J Cancer 2025;218:115262.
PMID: 39919334